The Department of Health has decided to remove Etoposide Preparation under Government-Mediated Access Price (GMAP). To learn more about the changes, you can access the full contents here.
Removal of Methotrexate and Mitomycin Preparations in the Government Mediated Access Price (GMAP) List
The Department of Health has decided to remove several medicines under Government-Mediated Access Price (GMAP). To learn more about the changes, you can access the full contents here.
Government-Mediated Access Price (GMAP) Adjustment of Salmeterol + Fluticasone Propionate
The department of health have adjusted the price of several medicines under Government-Mediated Access Price (GMAP). To know more regarding the changes you can access the full contents here.
Government-Mediated Access Price (GMAP) Adjustment of Co-Amoxiclav, Dutasteride and Paroxetine
The department of health have adjusted the price of several medicines under Government-Mediated Access Price (GMAP). To know more regarding the changes you can access the full contents here.
Removal of Metronidazole and Glibenclamide Preparations in the Government-Mediated Access Price (GMAP) List
The Department of Health has removed certain medicines from the Government-Mediated Access Price (GMAP) list. For more details on these changes, you can access the full information of the circular here.
Advisory on the adjustments in the price of the medicines under GMAP
The department of health have adjusted the price of several medicines under Government-Mediated Access Price (GMAP). To know more regarding the changes you can access the full contents here.
Advisory on the Delistment of Piperacillin + Tazobactam Preparations in the Government Mediated Access Price (GMAP) List
Delistment of Piperacillin + Tazobactam Preparations in the Government Mediated Access Price (GMAP) List. Click the link to know more regarding the advisory.
Duterte Legacy Summit highlights DOH efforts on setting Maximum Retail Price for high-cost medicines
The DOH Pharmaceutical Division expresses its gratitude to the leadership and concern for poor and vulnerable Filipino patients shown by President Rodrigo Duterte with the passage of two landmark Executive Orders which set maximum retail price to 120 high cost medicines.
DOH Announces Full Implementation of Drug Price Caps with Executive Order No. 155
The Department of Health (DOH) announces the full implementation of drug price caps starting March 23, 2022 through Executive Order (EO) No. 155 signed by President Rodrigo Duterte. This brings the total number of drugs with maximum drug retail price to 121 molecules or 204 drug formulas, following the first round of price regulation implemented in June 2020 with the signing of EO No. 104 which covered 87 molecules.
Standard Information, Education and Communication (IEC) Materials for the Implementation of Maximum Drug Retail Price through Executive Order No. 155 s. 2021
The Executive Order (EO) No. 155, “Further Improving Access to Healthcare Through the Regulation of Prices in the Retail of Drugs and Medicines,” which was issued by President Rodrigo R. Duterte on 07 December 2021, subjected 34 drug molecules or 71 drug formulas under price regulation through Maximum Wholesale Price (MWP) and Maximum Retail Price (MRP). The implementation shall begin on 23 March 2022.